Resistance signatures manifested in early drug response across cancer types and species

Abstract

Aim: Growing evidence points to non-genetic mechanisms underlying long-term resistance to cancer therapies. These mechanisms involve pre-existing or therapy-induced transcriptional cell states that confer resistance. However, the relationship between early transcriptional responses to treatment and the eventual emergence of resistant states remains poorly understood. Furthermore, it is unclear whether such early resistance-associated transcriptional responses are evolutionarily conserved. In this study, we examine the similarity between early transcriptional responses and long-term resistant states, assess their clinical relevance, and explore their evolutionary conservation across species.

Methods: We integrated datasets on early drug responses and long-term resistance from multiple cancer cell lines, bacteria, and yeast to identify early transcriptional changes predictive of long-term resistance and assess their evolutionary conservation. Using genome-wide CRISPR-Cas9 knockout screens, we evaluated the impact of genes associated with resistant transcriptional states on drug sensitivity. Clinical datasets were analyzed to explore the prognostic value of the identified resistance-associated gene signatures.

Results: We found that transcriptional states observed in drug-naive cells and shortly after treatment overlapped with those seen in fully resistant populations. Some of these shared features appear to be evolutionarily conserved. Knockout of genes marking resistant states sensitized ovarian cancer cells to Prexasertib. Moreover, early resistance gene signatures effectively distinguished therapy responders from non-responders in multiple clinical cancer trials and differentiated premalignant breast lesions that progressed to malignancy from those that remained benign.

Conclusion: Early cellular transcriptional responses to therapy exhibit key similarities to fully resistant states across different drugs, cancer types, and species. Gene signatures defining these early resistance states have prognostic value in clinical settings.

Keywords

Cancer / resistance / epigenetics / transcription / CRISPR / evolution / therapy response

References

[1] Ramos A,Tabatabaeian H.Battling chemoresistance in cancer: root causes and strategies to uproot them.Int J Mol Sci2021;22:9451 PMCID:PMC8430957

[2] Lei ZN,Teng QX.Understanding and targeting resistance mechanisms in cancer.MedComm2023;4:e265 PMCID:PMC10203373

[3] Nussinov R,Jang H.Anticancer drug resistance: an update and perspective.Drug Resist Updat2021;59:100796 PMCID:PMC8810687

[4] Frank SA.Nonheritable cellular variability accelerates the evolutionary processes of cancer.PLoS Biol2012;10:e1001296 PMCID:PMC3317895

[5] Bell CC,Chan YC.Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.Nat Commun2019;10:2723 PMCID:PMC6586637

[6] Sharma SV,Li B.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.Cell2010;141:69-80 PMCID:PMC2851638

[7] Marine JC,Dawson MA.Non-genetic mechanisms of therapeutic resistance in cancer.Nat Rev Cancer2020;20:743-56

[8] Goyal Y,Pillai M.Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells.Nature2023;620:651-9 PMCID:PMC10628994

[9] Oren Y,Cuoco MS.Cycling cancer persister cells arise from lineages with distinct programs.Nature2021;596:576-82 PMCID:PMC9209846

[10] Bigger JW.Treatment of staphylococcal infections with penicillin by intermittent sterilisation.Lancet1944;244:497-500

[11] Srivatsan SR,Ramani V.Massively multiplex chemical transcriptomics at single-cell resolution.Science2020;367:45-51 PMCID:PMC7289078

[12] Bie L,Wang J.Comparative analysis of transcriptomic response of Escherichia coli K-12 MG1655 to nine representative classes of antibiotics.Microbiol Spectr2023;11:e0031723 PMCID:PMC10100721

[13] Zhou W,Lin Y.A comparative transcriptome between anti-drug sensitive and resistant Candida auris in China.Front Microbiol2021;12:708009 PMCID:PMC8330549

[14] Hao Y,Kowalski MH.Dictionary learning for integrative, multimodal and scalable single-cell analysis.Nat Biotechnol2024;42:293-304 PMCID:PMC10928517

[15] Kolde R,Adler P.Robust rank aggregation for gene list integration and meta-analysis.Bioinformatics2012;28:573-80 PMCID:PMC3278763

[16] Korotkevich G,Budin N,Artyomov MN.Fast gene set enrichment analysis.bioRxiv2016;

[17] Wu T,Xu S.clusterProfiler 4.0: a universal enrichment tool for interpreting omics data.Innovation2021;2:100141 PMCID:PMC8454663

[18] Liberzon A,Thorvaldsdóttir H,Mesirov JP.The Molecular Signatures Database (MSigDB) hallmark gene set collection.Cell Syst2015;1:417-25 PMCID:PMC4707969

[19] Gavish A,Greenwald AC.Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours.Nature2023;618:598-606

[20] Aibar S,Moerman T.SCENIC: single-cell regulatory network inference and clustering.Nat Methods2017;14:1083-6 PMCID:PMC5937676

[21] Wiecek AJ,Kornai D.Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer.Genome Biol2023;24:128 PMCID:PMC10204193

[22] Li W,Xiao T.MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens.Genome Biol2014;15:554 PMCID:PMC4290824

[23] Kassambara A,Biecek P. survminer: Drawing Survival Curves using ‘ggplot2’. 2024. Available from: https://rpkgs.datanovia.com/survminer/index.html. [Last accessed on 5 Aug 2025]

[24] Hänzelmann S,Guinney J.GSVA: gene set variation analysis for microarray and RNA-seq data.BMC Bioinformatics2013;14:7 PMCID:PMC3618321

[25] Therneau T. A package for survival analysis in R. 2024. Available from: https://CRAN.R-project.org/package=survival. [Last accessed on 5 Aug 2025]

[26] Altenhoff AM,Gilbert KJ.OMA orthology in 2021: website overhaul, conserved isoforms, ancestral gene order and more.Nucleic Acids Res2021;49:D373-9 PMCID:PMC7779010

[27] Smith BN.Role of EMT in metastasis and therapy resistance.J Clin Med2016;5:17 PMCID:PMC4773773

[28] Jing X,Shao C.Role of hypoxia in cancer therapy by regulating the tumor microenvironment.Mol Cancer2019;18:157 PMCID:PMC6844052

[29] Wu Y.TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion.Br J Cancer2010;102:639-44 PMCID:PMC2837572

[30] Abd GM,Ku JC.Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise.Front Oncol2023;13:1227884 PMCID:PMC10442830

[31] Donati G.MYC and therapy resistance in cancer: risks and opportunities.Mol Oncol2022;16:3828-54 PMCID:PMC9627787

[32] Doha ZO.Unraveling MYC’s role in orchestrating tumor intrinsic and tumor microenvironment interactions driving tumorigenesis and drug resistance.Pathophysiology2023;30:400-19 PMCID:PMC10537413

[33] Zhao Z,Wang Z.The effect of oxidative phosphorylation on cancer drug resistance.Cancers2022;15:62 PMCID:PMC9817696

[34] Housman G,Heerboth S.Drug resistance in cancer: an overview.Cancers2014;6:1769-92 PMCID:PMC4190567

[35] Kluska M,Tokarz P.Cell cycle status influences resistance to apoptosis induced by oxidative stress in human breast cancer cells, which is accompanied by modulation of autophagy.Curr Issues Mol Biol2023;45:6325-38 PMCID:PMC10453102

[36] Vallette FM,Lézot F.Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer.Biochem Pharmacol2019;162:169-76

[37] King C,McNeely S.LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms.Mol Cancer Ther2015;14:2004-13

[38] Gurule NJ,Hinz TK.A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer.NPJ Precis Oncol2021;5:41 PMCID:PMC8129124

[39] Dinstag G,Elis E.Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.Med2023;4:15-30.e8 PMCID:PMC10029756

[40] Rozenblatt-Rosen O, Regev A, Oberdoerffer P, et al; Human Tumor Atlas Network. The Human Tumor Atlas Network: charting tumor transitions across space and time at single-cell resolution. Cell. 2020;181:236-49. PMCID:PMC7376497

[41] de Bruijn I,Lau C.Sharing data from the Human Tumor Atlas Network through standards, infrastructure and community engagement.Nat Methods2025;22:664-71 PMCID:PMC12125965

[42] Destefanis F,Bellosta P.Myc as a regulator of ribosome biogenesis and cell competition: a link to cancer.Int J Mol Sci2020;21:4037 PMCID:PMC7312820

[43] van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis.Nat Rev Cancer2010;10:301-9

[44] Sun N,Zhang Y,Groutas W.Repurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity.Sci Rep2017;7:17014 PMCID:PMC5717060

[45] Elhamamsy AR,Alsheikh HA,Samant RS.Ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance.Cancer Res2022;82:2344-53 PMCID:PMC9256764

[46] Wasi M,Moorhouse AJ.ABC transporter genes show upregulated expression in drug-resistant clinical isolates of Candida auris: a genome-wide characterization of ATP-binding cassette (ABC) transporter genes.Front Microbiol2019;10:1445 PMCID:PMC6647914

[47] Fan J,Chen ZS.ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance.Drug Resist Updat2023;66:100905

[48] Sass TH.The DNA damage response of Escherichia coli, revisited: differential gene expression after replication inhibition.Proc Natl Acad Sci U S A2024;121:e2407832121 PMCID:PMC11228462

[49] Li LY,Chen XS,Cheng Y.DNA repair pathways in cancer therapy and resistance.Front Pharmacol2020;11:629266 PMCID:PMC7898236

[50] De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies.Arch Toxicol2021;95:2279-97 PMCID:PMC8241801

[51] Cui W,Wei L,Tian X.High heterogeneity undermines generalization of differential expression results in RNA-Seq analysis.Hum Genomics2021;15:7 PMCID:PMC7845028

[52] Crow M,Ballouz S,Gillis J.Predictability of human differential gene expression.Proc Natl Acad Sci U S A2019;116:6491-500 PMCID:PMC6442595

[53] Terrones-Campos C,Specht L,Helleberg M.Risk of bacterial, viral, and fungal infections in patients with solid malignant tumors treated with curative intent radiation therapy.Adv Radiat Oncol2022;7:100950 PMCID:PMC9168504

[54] Menzin J,Friedman M,Marton JP.Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data.Value Health2005;8:140-8

[55] He J,Fan J,Sheng Q.Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies.Signal Transduct Target Ther2024;9:209 PMCID:PMC11322379

[56] Robinson K.Perplexing role of P-glycoprotein in tumor microenvironment.Front Oncol2020;10:265 PMCID:PMC7066112

[57] Garg P,Kulkarni P,Salgia R.Emerging therapeutic strategies to overcome drug resistance in cancer cells.Cancers2024;16:2478 PMCID:PMC11240358